Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia

ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document)

Alice Cani (Creator)

Silvano Capitani (Creator)

Alberto M. Martelli (Creator)

James A. McCubrey (Creator)

Luca M. Neri (Creator)

Carolina Simioni (Creator)

Giovanna Tabellini (Creator)

Simona Ultimo (Creator)

Giorgio Zauli (Creator)

Institution

East Carolina University (ECU )

Web Site: http://www.ecu.edu/lib/

Abstract: Poster as presented; T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive neoplastic disorder in which chemotherapy resistance and refractory relapses occur, with a poorer prognostic outcome. Constitutively active PI3K/Akt/mTOR pathway is a common feature of T-ALL upregulating cell proliferation, survival and drug resistance. This pathway is currently under clinical trials with small molecules inhibitors (SMI). To verify whether a multi-inhibition treatment against Akt protein could enhance the efficacy of individual drug administration and overcome drug resistance as well as to obtain a decrease in single drug concentration, we tested on T-ALL cell lines the effects of combined treatments with three Akt inhibitors with different mode of action, GSK690693, MK-2206 and Perifosine. In cells with hyperactivated Akt, combined administration of the drugs displayed a significant synergistic and cytotoxic effect and affected PI3K/Akt/mTOR pathway at much lower concentration than single drug use. Highest synergistic effect for full inhibition of Akt was also related to the timing of every drug administration. Furthermore the triple treatment had greater efficacy in inducing cell cycle arrest in G0/G1 phase and both apoptosis and autophagy. Targeting Akt as a key protein of PI3K/Akt/mTOR pathway with multiple drugs might represent a new and promising pharmacological strategy for treatment of T-ALL patients.

Additional Information

Publication

Other

Oncotarget; 6:9 p. 6597-6610

Language: English

Date: 2015

Keywords

GSK690693, Akt, Perifosine, MK-2206, T-acute lymphoblastic leukemia

Email this document to